Published in

Elsevier, The Lancet Oncology, 10(20), p. 1444-1453, 2019

DOI: 10.1016/s1470-2045(19)30502-9

Links

Tools

Export citation

Search in Google Scholar

Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

Journal article published in 2019 by Johannes Weller, Theophilos Tzaridis ORCID, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel, Peter Hau, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Oliver Bähr, Martin Uhl, Clemens Seidel, Ghazaleh Tabatabai ORCID, Stefanie Brehmer, Lars Bullinger and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO